Vectus Biosystems (ASX:VBS) Capex-to-Revenue

: 4.22 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Vectus Biosystems's Capital Expenditure for the six months ended in Dec. 2022 was A$-0.04 Mil. Its Revenue for the six months ended in Dec. 2022 was A$0.01 Mil.

Hence, Vectus Biosystems's Capex-to-Revenue for the six months ended in Dec. 2022 was 4.22.

Vectus Biosystems Capex-to-Revenue Historical Data

The historical data trend for Vectus Biosystems's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Capex-to-Revenue

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
Capex-to-Revenue										-	-	-	-	4.22

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Vectus Biosystems Capex-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Capex-to-Revenue falls in comparison to its industry or sector. The grey bar indicates the Capex-to-Revenue's extreme value range as defined by GuruFocus.

Vectus Biosystems Capex-to-Revenue Calculation

Vectus Biosystems's Capex-to-Revenue for the fiscal year that ended in Jun. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Vectus Biosystems's Capex-to-Revenue for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.038)	/	0.009
	=	4.22

Vectus Biosystems (ASX:VBS) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Vectus Biosystems Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

http://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines